CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Cash Flows From Operating Activities:
Net loss	$ (117,500)	$ (95,708)	$ (62,124)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	163	120	56
Amortization of deferred financing costs	4,566	411
Value of common stock issued for patent license	67
Stock-based compensation expense	9,724	4,722	4,614
Accretion of discount/premium on available for sale securities	(109)	130	59
Change in fair value of derivative instruments-warrants	394	(1,362)	(149)
Changes in operating assets and liabilities:
Security deposit	(180)	(69)
Accounts payable and accrued expenses	1,867	316	7,084
Prepaid expenses and other current assets	531	(124)	(2,171)
Accrued interest expense on Senior Convertible Debentures	(512)	2,500
Total Adjustments	16,511	6,644	9,493
Net Cash used in Operating Activities	(100,989)	(89,064)	(52,631)
Cash Flows From Investing Activities:
Loans to related parties			(270)
Net purchases of available-for-sale securities	(200)		(30,000)
Additions to property and equipment	(50)	(173)	(615)
Repayment on ContraVir loan receivable		455
Net Cash provided by/(used in) Investing Activities	(250)	282	(30,885)
Cash Flows From Financing Activities:
Proceeds of sale of common stock	14,672	30,700	94,734
Proceeds of sale of common stock - ContraVir		3,224
Issuance of Senior Convertible Debentures		200,000
Payment for debt financing costs		(12,747)
Fees and expenses related to sale of common stock	(404)	(861)	(5,623)
Proceeds from exercise of stock options	1,142	36	119
Proceeds from exercise of warrants	1,012
Distribution associated with ContraVir Spinoff		(3,230)
Net Cash provided by Financing Activities	16,422	217,122	89,230
Net increase/(decrease) in cash and cash equivalents	(84,817)	128,340	5,714
Cash and cash equivalents at beginning of period	146,470	18,130	12,416
Cash and cash equivalents at end of period	61,653	146,470	18,130
Supplementary disclosure of cash flow information:
Cash paid for interest on Senior Convertible Debentures	13,379
Cash paid for taxes	258	55	$ 81
Supplementary disclosure of non-cash investing and financing activities:
Distribution of net assets of ContraVir		$ 84
Conversion of Senior Convertible Debentures to Synergy Common Stock	$ 40,989